Dec 24 (Reuters) - Shares of Agios Pharmaceuticals (AGIO) jumped 18% on Wednesday after the U.S. Food and Drug Administration approved the expanded use of its drug for the treatment of a type of blood disorder.
The drug mitapivat is now approved as a treatment for patients with anemia in both non-transfusion-dependent and transfusion-dependent alpha- or beta-thalassemia, the company said late on Tuesday.
Thalassemia is an inherited blood disorder affecting the body's ability to produce hemoglobin and healthy red blood cells.
The drug, under the brand name Aqvesme, is expected to be available in late January next year, following the implementation of the required safety program.
Mitapivat was already approved by the U.S. FDA in 2022 to treat low red blood cell counts in adults with pyruvate kinase deficiency, under the brand name of Pyrukynd.
"The approval unlocks an additional $320 million in peak revenue opportunity layered atop the existing mitapivat franchise," Truist analyst Gregory Renza said.
The latest approval is based on a late-stage study in which patients receiving mitapivat showed a statistically significant increase in hemoglobin response compared to those on placebo.
Aqvesme will carry a boxed warning for liver function tests every four weeks during the first 24 weeks of treatment and advises against use in patients with cirrhosis, Renza added.
(Reporting by Siddhi Mahatole in Bengaluru; Editing by Vijay Kishore)
LATEST POSTS
- 1
UAE recalls some Nestle infant formula products, Qatar warns consumers - 26 Top of the line Lodgings All over The Planet, Which One Do You Concur With
- 3The Response to Independence from the rat race: Methodologies for Creating Financial momentum
- 4The most effective method to Decisively Use Open Record Rewards
- 5Go With The Breeze: Grand Paragliding Spots On the planet
- German diesel hits new records over Easter weekend
- 4 injured in suburban Philadelphia nursing home explosion file negligence lawsuit
- 4 Famous Gaming PCs of 2024: Execution, Versatility, and Advancement
- Fabricated statement about Malaysian national exam top scorers stokes racial sentiment
- Deadly attack on kindergarten reported in Sudan
- Google's proposed data center in orbit will face issues with space debris in an already crowded orbit
- ‘Everybody Loves Raymond: 30th Anniversary Reunion’ premiere date: How to watch, channel, time, cast and more
- 'Seditious behavior': Trump accuses Democrats who made video reminding the military not to follow illegal orders of a crime — but is it?
- Why is Jerome Powell being investigated? Making sense of the DOJ's probe into the Federal Reserve chair.
